content: <HTML>
  <HEAD>
  <TITLE></TITLE>
  </HEAD>
  <BODY>
  
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">UNITED STATES</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">FORM 8-K</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">CURRENT REPORT</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Pursuant to Section 13 or 15 (d) of the</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities Exchange Act of 1934</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
  September 3, 2013</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">GLOBAL BIOTECH CORP..</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
  charter)</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">Delaware</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction of incorporation)</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; font: 12pt Times New Roman, Times, Serif; width: 65%">
  <TR STYLE="vertical-align: top; text-align: left">
      <TD STYLE="width: 49%; text-align: center; vertical-align: bottom">(Commission file no.)</TD>
      <TD STYLE="width: 2%">&nbsp;</TD>
      <TD STYLE="width: 49%; text-align: center; vertical-align: bottom">(IRS Employer Identification No.)</TD></TR>
  <TR STYLE="vertical-align: top; text-align: left">
      <TD STYLE="text-align: center; vertical-align: bottom">000-33271</TD>
      <TD>&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">98-022951</TD></TR>
  </TABLE>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">2711, CENTREVILLE ROAD, BUREAU 400</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">WILMINGTON, DELAWARE 19808</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0pt">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0pt">Company's telephone number,
  including area code:</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">302-288-0658</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
  
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>Item 1.01 Entry into a Material Definitive Agreement</B></P>
  
  <P STYLE="font: 12pt Courier New, Courier, Monospace; margin: 0">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 3, 2013, Global Biotech Corp.
  (the Company&quot; or &quot;Global&quot;) entered into an Agreement in principal, with a finalized agreement to be signed within
  the following 2 weeks, with Purthanol Ltd. to acquire their know-how and all technical aspects of the purthanol extraction process.
  Further, they also acquired all purchase orders on hand (for forward delivery of purthanol within the next 12 months) and licensing
  agreements, currently signed or in the process of being signed, for the purthanol extraction process. The consideration for all
  the above are common shares of Global. A part of said agreement is a non-compete clause with Global.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><B>Item 5.02 Departure and Appointment of
  Directors or Certain Officers</B></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 3, 2013, Louis Greco resigned
  as a Director and the President of Global Biotech Corp.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective September 3, 2013, Louis Pharand was appointed the President
  and a Director of the Company. Mr.Pharand&#8217;s appointment was confirmed at a meeting of the Board of Directors of the Company
  held on the same day. Mr. Pharand aged 59, will serve as the President of the company until further notice.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr.Louis Pharand is currently the president
  of Purthanol Ltd. and the moving force behind the implementation of the purthanol process, worldwide.&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Pharand has been the presidential pilot
  for H.E.M. Marc Ravalomanana of Madagascar&nbsp;and has worked alongside the Chief of Staff to the President, as a consultant
  for foreign delegations and corporations looking to do business in Madagascar and other countries.&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Pharand also has an expertise in providing
  security to heads of states.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr Pharand is presently active in the coordination
  and implementation of several projects, primarily purthanol, through his many contacts in the business world. His ability to implement
  programs and to communicate directly with heads of states and international business people have created an infrastructure to make
  this venture a success.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective September 3, 2013, Serge Mersilian was appointed the Director
  of Communications of the Company. Mr. Mersilian&#8217;s appointment was confirmed at a meeting of the Board of Directors of the
  Company held on the same day. Mr. Mersilian aged 57, will serve in that capacity until further notice.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. Mersilian has dealt with a variety of highly
  sought after clients, through the use of various medias, during the past 30years. He has been involved with filmmaking, photographing,
  conceptualization of corporate logos, image creation etc. for many internationally known clients. These have included, to name
  some of them, L&#8217;Oreal, Chanel, Thomson, Essilor, Nabisco, Seagrams, etc. He has work credentials in Europe and North America
  and brings to Global the ability to raise the profile of the Company, on the worldwide stage, to great heights.</P>
  
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Signatures</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">Pursuant to the requirements of the Securities
  Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Date: September 3 2013</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Global Biotech Corp.</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">By: /s/ Leonard Stella</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">Leonard Stella, CEO</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>
  
  <P STYLE="font: 12pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0">&nbsp;</P>
  
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "gbiq8k0903.htm", "secsgml_size_bytes": 11557}]
metadata_filer: {"company-data": {"conformed-name": "Global Biotech Corp.", "cik": "0001126162", "assigned-sic": "7389", "irs-number": "980229951", "fiscal-year-end": "0228"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33271", "film-number": "131074712"}, "business-address": {"street1": "2550 BATES RD.", "street2": "SUITE 212", "city": "MONTREAL", "state": "A8", "zip": "H3S 1A7", "phone": "302 288 0658"}, "mail-address": {"street1": "2711 CENTERVILLE", "street2": "SUITE 400", "city": "WILMINGTON", "state": "DE", "zip": "19808"}, "former-company": {"former-conformed-name": "SWORD COMP SOFT CORP", "date-changed": "20001011"}}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15 (d) of the
  Securities Exchange Act of 1934
  Date of Report (Date of earliest event reported):
  September 3, 2013
  GLOBAL BIOTECH CORP..
  (Exact name of registrant as specified in its
  charter)
  Delaware
  (State or other jurisdiction of incorporation)
  (Commission file no.)
  (IRS Employer Identification No.)
  000-33271
  98-022951
  2711, CENTREVILLE ROAD, BUREAU 400
  WILMINGTON, DELAWARE 19808
  Company's telephone number,
  including area code:
  302-288-0658
  Item 1.01 Entry into a Material Definitive Agreement
  On September 3, 2013, Global Biotech Corp.
  (the Company" or "Global") entered into an Agreement in principal, with a finalized agreement to be signed within
  the following 2 weeks, with Purthanol Ltd. to acquire their know-how and all technical aspects of the purthanol extraction process.
  Further, they also acquired all purchase orders on hand (for forward delivery of purthanol within the next 12 months) and licensing
  agreements, currently signed or in the process of being signed, for the purthanol extraction process. The consideration for all
  the above are common shares of Global. A part of said agreement is a non-compete clause with Global.
  Item 5.02 Departure and Appointment of
  Directors or Certain Officers
  On September 3, 2013, Louis Greco resigned
  as a Director and the President of Global Biotech Corp.
  Effective September 3, 2013, Louis Pharand was appointed the President
  and a Director of the Company. Mr.Pharand's appointment was confirmed at a meeting of the Board of Directors of the Company
  held on the same day. Mr. Pharand aged 59, will serve as the President of the company until further notice.
  Mr.Louis Pharand is currently the president
  of Purthanol Ltd. and the moving force behind the implementation of the purthanol process, worldwide.
  Mr. Pharand has been the presidential pilot
  for H.E.M. Marc Ravalomanana of Madagascar and has worked alongside the Chief of Staff to the President, as a consultant
  for foreign delegations and corporations looking to do business in Madagascar and other countries.
  Mr. Pharand also has an expertise in providing
  security to heads of states.
  Mr Pharand is presently active in the coordination
  and implementation of several projects, primarily purthanol, through his many contacts in the business world. His ability to implement
  programs and to communicate directly with heads of states and international business people have created an infrastructure to make
  this venture a success.
  Effective September 3, 2013, Serge Mersilian was appointed the Director
  of Communications of the Company. Mr. Mersilian's appointment was confirmed at a meeting of the Board of Directors of the
  Company held on the same day. Mr. Mersilian aged 57, will serve in that capacity until further notice.
  Mr. Mersilian has dealt with a variety of highly
  sought after clients, through the use of various medias, during the past 30years. He has been involved with filmmaking, photographing,
  conceptualization of corporate logos, image creation etc. for many internationally known clients. These have included, to name
  some of them, L'Oreal, Chanel, Thomson, Essilor, Nabisco, Seagrams, etc. He has work credentials in Europe and North America
  and brings to Global the ability to raise the profile of the Company, on the worldwide stage, to great heights.
  Signatures
  Pursuant to the requirements of the Securities
  Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  Date: September 3 2013
  Global Biotech Corp.
  By: /s/ Leonard Stella
  Leonard Stella, CEO